HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk (Q40410928)

20 September 2017

HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk (English)

1 reference

20 September 2017

Barbara A Wible

1

1 reference

20 September 2017

Peter Hawryluk

2

1 reference

20 September 2017

Eckhard Ficker

3

1 reference

20 September 2017

Yuri A Kuryshev

4

1 reference

20 September 2017

Glenn Kirsch

5

1 reference

20 September 2017

Arthur M Brown

6

1 reference

20 September 2017

1 July 2005

1 reference

Journal of Pharmacological and Toxicological Methods

20 September 2017

1 reference

20 September 2017

52

1 reference

20 September 2017

1

1 reference

20 September 2017

136-145

1 reference

Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go-related gene channels

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

Mechanisms of arsenic-induced prolongation of cardiac repolarization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

[3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

Novel mechanism associated with an inherited cardiac arrhythmia: defective protein trafficking by the mutant HERG (G601S) potassium channel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

Dopamine receptor agonists differ in their actions on cardiac ion channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

Pentamidine-induced long QT syndrome and block of hERG trafficking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

Drug binding to HERG channels: evidence for a 'non-aromatic' binding site for fluvoxamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

Variability of the QTc interval: impact on defining drug effect and low-frequency cardiac event

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

Direct measurement of cell numbers in microtitre plate cultures using the fluorescent dye SYBR green I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

Rb+ flux through hERG channels affects the potency of channel blocking drugs: correlation with data obtained using a high-throughput Rb+ efflux assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

Functional analysis of native and recombinant ion channels using a high-capacity nonradioactive rubidium efflux assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

Inhibition of HERG channels stably expressed in a mammalian cell line by the antianginal agent perhexiline maleate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

Cardiac actions of antihistamines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

Ion-channel assay technologies: quo vadis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

Vinpocetine Is a Potent Blocker of Rat NaV1.8 Tetrodotoxin-Resistant Sodium Channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.03.008

10.1016/J.VASCN.2005.03.008

7 January 2021

Identifiers

DOI

1 reference

20 September 2017

1 reference